These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37385955)

  • 41. Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?
    Fernandez-Fernandez B; Fernandez-Prado R; Górriz JL; Martinez-Castelao A; Navarro-González JF; Porrini E; Soler MJ; Ortiz A
    Clin Kidney J; 2019 Jun; 12(3):313-321. PubMed ID: 31198532
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V
    Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial.
    Persson F; Bain SC; Mosenzon O; Heerspink HJL; Mann JFE; Pratley R; Raz I; Idorn T; Rasmussen S; von Scholten BJ; Rossing P;
    Diabetes Care; 2021 Apr; 44(4):1020-1026. PubMed ID: 33504496
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study in Japan.
    Wada T; Mori-Anai K; Takahashi A; Matsui T; Inagaki M; Iida M; Maruyama K; Tsuda H
    J Diabetes Investig; 2022 Dec; 13(12):1981-1989. PubMed ID: 35861630
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined changes in albuminuria and kidney function and subsequent risk for kidney failure in type 2 diabetes.
    Oshima M; Toyama T; Hara A; Shimizu M; Kitajima S; Iwata Y; Sakai N; Furuichi K; Haneda M; Babazono T; Yokoyama H; Iseki K; Araki SI; Ninomiya T; Hara S; Suzuki Y; Iwano M; Kusano E; Moriya T; Satoh H; Nakamura H; Makino H; Wada T
    BMJ Open Diabetes Res Care; 2021 Jun; 9(1):. PubMed ID: 34193460
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial.
    Li JW; Arnott C; Heerspink HJL; MBiostat QL; Cannon CP; Wheeler DC; Charytan DM; Barraclough J; Figtree GA; Agarwal R; Bakris G; de Zeeuw D; Greene T; Levin A; Pollock C; Zhang H; Zinman B; Mahaffey KW; Perkovic V; Neal B; Jardine MJ
    J Am Heart Assoc; 2022 Aug; 11(16):e025045. PubMed ID: 35929472
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA
    Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M
    Diabetologia; 2021 Nov; 64(11):2402-2414. PubMed ID: 34448033
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sodium-glucose linked transporter-2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk.
    Schernthaner G; Groop PH; Kalra PA; Ronco C; Taal MW
    Diabetes Obes Metab; 2020 Jul; 22(7):1024-1034. PubMed ID: 32037647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
    Mahaffey KW; Jardine MJ; Bompoint S; Cannon CP; Neal B; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Capuano G; de Zeeuw D; Greene T; Levin A; Pollock C; Sun T; Wheeler DC; Yavin Y; Zhang H; Zinman B; Rosenthal N; Brenner BM; Perkovic V
    Circulation; 2019 Aug; 140(9):739-750. PubMed ID: 31291786
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
    Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
    Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
    Mosenzon O; Wiviott SD; Heerspink HJL; Dwyer JP; Cahn A; Goodrich EL; Rozenberg A; Schechter M; Yanuv I; Murphy SA; Zelniker TA; Gause-Nilsson IAM; Langkilde AM; Fredriksson M; Johansson PA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS; Raz I
    Diabetes Care; 2021 Aug; 44(8):1805-1815. PubMed ID: 34233928
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial.
    Yu J; Sweeting AN; Gianacas C; Houston L; Lee V; Fletcher RA; Perkovic V; Li Q; Neuen BL; Berwanger O; Heerspink HJL; de Zeeuw D; Arnott C
    Diabetes Obes Metab; 2023 Dec; 25(12):3724-3735. PubMed ID: 37671609
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
    Dekkers CCJ; Wheeler DC; Sjöström CD; Stefansson BV; Cain V; Heerspink HJL
    Nephrol Dial Transplant; 2018 Nov; 33(11):2005-2011. PubMed ID: 29370424
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.
    Weir MR; Gogate J; Damaraju CV; Correa-Rotter R; Mahaffey KW
    Diabetes Obes Metab; 2022 Jan; 24(1):12-20. PubMed ID: 34463423
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of Glycosuria in SGLT2 Inhibitor-Induced Cardiorenal Protection: A Mechanistic Analysis of the CREDENCE Trial.
    Ferrannini E; Solini A; Baldi S; Scozzaro T; Polidori D; Natali A; Hansen MK
    Diabetes; 2024 Feb; 73(2):250-259. PubMed ID: 37939214
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
    Jardine MJ; Mahaffey KW; Neal B; Agarwal R; Bakris GL; Brenner BM; Bull S; Cannon CP; Charytan DM; de Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Pollock C; Wheeler DC; Xie J; Zhang H; Zinman B; Desai M; Perkovic V;
    Am J Nephrol; 2017 Dec; 46(6):462-472. PubMed ID: 29253846
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.
    Heerspink HJL; Sjöström CD; Inzucchi SE; Hallow MK; Cain VA; Rossing P; Stefansson BV; Sartipy P
    Diabetes Obes Metab; 2019 Mar; 21(3):720-725. PubMed ID: 30414240
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
    Kang A; Smyth B; Neuen BL; Heerspink HJL; Di Tanna GL; Zhang H; Arnott C; Hockham C; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Mahaffey KW; Perkovic V; Jardine MJ
    Diabetes Obes Metab; 2023 Aug; 25(8):2151-2162. PubMed ID: 37161691
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.
    Muskiet MHA; Tonneijck L; Huang Y; Liu M; Saremi A; Heerspink HJL; van Raalte DH
    Lancet Diabetes Endocrinol; 2018 Nov; 6(11):859-869. PubMed ID: 30292589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.